Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Current pharmaceutical design

• Publication date

  2011-11-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/138161211798999456PMID 22204436
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats.

  2011cited by this paper
• Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

  2011cited by this paper
• Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level.

  2011cited by this paper
• Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.

  2011cited by this paper
• Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury.

  2011cited by this paper
• Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies.

  2011cited by this paper
• Neuroprotective effect of the glucagon‐like peptide‐1 receptor agonist, synthetic exendin‐4, in streptozotocin‐induced diabetic rats

  2011cited by this paper
• Glucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control

  2011cited by this paper
• Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression.

  2010cited by this paper
• Advanced glycation end products, oxidative stress and diabetic nephropathy

  2010cited by this paper
• Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations.

  2010cited by this paper
• RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells

  2010cited by this paper
• Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation.

  2010cited by this paper
• The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats

  2010cited by this paper
• Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species–Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A

  2010cited by this paper
• Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model

  2010cited by this paper
• Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

  2010cited by this paper
• DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes.

  2010cited by this paper
• The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes

  2010cited by this paper
• The Cardiovascular Effects of GLP-1 Receptor Agonists

  2010cited by this paper
• Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression.

  2010cited by this paper
• Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications?

  2009cited by this paper
• Involvement of Toxic AGEs (TAGE) in the Pathogenesis of Diabetic Vascular Complications and Alzheimer's Disease

  2009cited by this paper
• Intensive insulin therapy decreases urinary MCP‐1 and ICAM‐1 excretions in incipient diabetic nephropathy

  2009cited by this paper
• Effects of hyperglycemia and oxidative stress on the glutamate transporters GLAST and system xc− in mouse retinal Müller glial cells

  2009cited by this paper
• Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors

  2009cited by this paper
• Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2.

  2009cited by this paper
• A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules.

  2009cited by this paper
• Metalloproteinase Expression in Monocytes and Macrophages and its Relationship to Atherosclerotic Plaque Instability

  2008cited by this paper
• Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes

  2008cited by this paper
• Inflammation at the molecular interface of atherogenesis: an anthropological journey.

  2008cited by this paper
• Protection of exendin-4 analogue in early experimental diabetic retinopathy

  2008cited by this paper
• Glucagon-like Peptide-1 (GLP-1) Diminishes Neuronal Degeneration and Death Caused by NGF Deprivation by Suppressing Bim Induction

  2008cited by this paper
• Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.

  2008cited by this paper
• Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

  2008cited by this paper
• Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine.

  2008cited by this paper
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1.

  2008cited by this paper
• Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications

  2008cited by this paper
• The Role of Incretins in Glucose Homeostasis and Diabetes Treatment

  2008cited by this paper
• G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes.

  2007cited by this paper
• Nifedipine, a Calcium-channel Blocker, Inhibits Advanced Glycation End-product-induced Expression of Monocyte Chemoattractant Protein-1 in Human Cultured Mesangial Cells

  2007cited by this paper
• Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells.

  2007cited by this paper
• Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy.

  2007cited by this paper
• Molecular mechanisms of diabetic nephropathy and its therapeutic intervention.

  2007cited by this paper
• Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin.

  2007cited by this paper
• Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.

  2007cited by this paper
• Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties.

  2007cited by this paper
• Depression of progenitor cell function by advanced glycation endproducts (AGEs): potential relevance for impaired angiogenesis in advanced age and diabetes.

  2006cited by this paper
• Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

  2006cited by this paper
• Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice.

  2006cited by this paper
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy.

  2005cited by this paper
• Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes.

  2005cited by this paper
• Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

  2004cited by this paper
• Central role of RAGE-dependent neointimal expansion in arterial restenosis.

  2003cited by this paper
• Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.

  2003cited by this paper
• Early retinal damage in experimental diabetes: electroretinographical and morphological observations.

  2002cited by this paper
• Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings.

  2002cited by this paper
• Palmitate-Induced Apoptosis of Microvascular Endothelial Cells and Pericytes

  2002cited by this paper
• Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties.

  2002cited by this paper
• Advanced Glycation End Product-induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor and Monocyte Chemoattractant Protein-1 in Human-cultured Mesangial Cells*

  2002cited by this paper
• Diabetes and advanced glycation endproducts

  2002cited by this paper
• Diabetes-induced dysfunction of the glutamate transporter in retinal Müller cells.

  2002cited by this paper
• Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes.

  2002cited by this paper
• Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes.

  2002cited by this paper
• Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy.

  2000cited by this paper
• Hyperglycemia and cardiovascular disease in type 2 diabetes.

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells

  1998cited by this paper
• AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept.

  1998cited by this paper
• Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats.

  1997cited by this paper
• Receptor-mediated toxicity to pericytes of advanced glycosylation end products: a possible mechanism of pericyte loss in diabetic microangiopathy.

  1995cited by this paper
• Tumour necrosis factor alpha‐induced oxidative burst in neutrophils adherent to fibronectin: effects of cyclic AMP‐elevating agents

  1995cited by this paper
• Vascular pericytes not only regulate growth, but also preserve prostacyclin-producing ability and protect against lipid peroxide-induced injury of co-cultured endothelial cells.

  1993cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Endothelin 1 mediates endothelial cell-dependent proliferation of vascular pericytes.

  1993cited by this paper
• Atherosclerotic plaque caps are locally weakened when macrophages density is increased.

  1991cited by this paper
• On the pathogenesis of diabetic retinopathy. A 1990 update.

  1991cited by this paper
• An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes.

  1989cited by this paper
• Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.

  1988cited by this paper
• The glomerular mesangial cell: an expanding role for a specialized pericyte

  1987cited by this paper
• Contractile properties of cultured glomerular mesangial cells.

  1985cited by this paper
• Hormonal modulation of glomerular function.

  1983cited by this paper

• Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review

  2025cites this paper
• Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus

  2025cites this paper
• Mechanisms of ferroptosis and glucagon-like peptide-1 receptor agonist in post-percutaneous coronary intervention restenosis

  2024cites this paper
• Potential Effects of Hyperglycemia on SARS-CoV-2 Entry Mechanisms in Pancreatic Beta Cells

  2024cites this paper
• The impact of diabetes in cognitive impairment: A review of current evidence and prospects for future investigations

  2023cites this paper
• Hypoglycemia, Vascular Disease and Cognitive Dysfunction in Diabetes: Insights from Text Mining-Based Reconstruction and Bioinformatics Analysis of the Gene Networks

  2021cites this paper
• GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential

  2021cites this paper
• A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression

  2020cites this paper
• Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.

  2019cites this paper
• Insulinotropic and glucose-lowering peptides from phylogenetically ancient fish with potential for therapy of type 2 diabetes

  2019cites this paper
• Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA

  2018cites this paper
• Advanced glycation end products evoke inflammatory reactions in proximal tubular cells via autocrine production of dipeptidyl peptidase-4.

  2018cites this paper
• The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review

  2018cites this paper
• GLP-1 receptor agonists, carotid atherosclerosis and retinopathy

  2017cites this paper
• Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes

  2017cites this paper
• INSIGHT INTO AMINOMETHYL-PIPERIDONES BASED DPP-IV INHIBITORS FOR TREATMENT OF DIABETES: AN APPLICATION OF RATIONAL DRUG DESIGN

  2017cites this paper
• After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?

  2017cites this paper
• Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients.

  2016cites this paper
• Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes

  2015cites this paper
• Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications

  2015cites this paper
• Serum levels of pigment epithelium-derived factor (PEDF) are inversely associated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans.

  2015cites this paper
• Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis

  2015cites this paper
• FACULDADE DE MEDICINA DA UNIVERSIDADE DE COIMBRA TRABALHO FINAL DO 6o ANO MÉDICO COM VISTA À ATRIBUIÇÃO DO GRAU DE MESTRE NO ÂMBITO DO CICLO DE ESTUDOS DE MESTRADO INTEGRADO EM MEDICINA

  2015cites this paper
• Effects of alogliptin in chronic kidney disease patients with type 2 diabetes.

  2014cites this paper
• Expression of glucagon-like peptide-1 receptor and glucose‑dependent insulinotropic polypeptide receptor is regulated by the glucose concentration in mouse osteoblastic MC3T3-E1 cells.

  2014cites this paper
• Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity.

  2014influential citation
• Linagliptin Blocks Renal Damage in Type 1 Diabetic Rats by Suppressing Advanced Glycation End Products-Receptor Axis

  2014cites this paper
• The effect of dipeptidyl peptidase‐IV inhibition on bone in a mouse model of type 2 diabetes

  2014cites this paper
• Antidiabetic therapy effects on bone metabolism and fracture risk

  2013cites this paper
• Efficacy of alogliptin, a dipeptidyl peptidase‐4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) – receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes

  2013cites this paper
• Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans.

  2013cites this paper
• Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor

  2013cites this paper
• Neuroprotective and neurotrophic actions of glucagon‐like peptide‐1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders

  2012cites this paper
• Vildagliptin: a DPP-4 inhibitor for the treatment of Type 2 diabetes

  2012cites this paper
• The role of inflammation in diabetic cardiomyopathy

  2012cites this paper
• What the future holds for gliptins

  2012cites this paper
• On- en off-targeteffecten van dipeptidyl peptidase-4-remmers

  2012cites this paper
• Vildagliptin DPP-4 inhibitor for the treatment of Type 2 diabetes Review

  2012cites this paper
• Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats.

  2012cites this paper